PET with florbetaben uncovers amyloid-Down syndrome link

07/11/2013 | (free registration)

PET with the investigational agent florbetaben has shed light on changes in the brains of patients with Down syndrome and offers an opportunity to study the early accumulation of beta amyloid, potentially informing the development of therapies to address amyloid buildup. Research led by Dr. John Seibyl of the Institute for Neurodegenerative Disorders found binding of beta-amyloid increased with age among patients with Down syndrome. The work was presented at the SNMMI Annual Meeting.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ